Natural Killer Cell Therapies - Pipeline Insight, 2021
This report can be delivered to the clients within 7-10 Business Days
DelveInsight’s, “Natural Killer Cell Therapies - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Natural Killer Cell Therapies: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cell abnormalities have been observed in several cancer patients, including decreased cytotoxicity, defective expression of activating receptors or intracellular signaling molecules, overexpression of inhibitory receptors, defective proliferation, and decreased numbers in peripheral blood and tumor infiltrate, and defective cytokine production. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. NK cell immunotherapy can be achieved in several ways
'Natural Killer Cell Therapies - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Natural Killer Cell Therapies pipeline landscape is provided which includes the disease overview and Natural Killer Cell Therapies treatment guidelines. The assessment part of the report embraces, in depth Natural Killer Cell Therapies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer Cell Therapies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Natural Killer Cell Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Natural Killer Cell Therapies Emerging Drugs
Further product details are provided in the report……..
Natural Killer Cell Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Natural Killer Cell Therapies drugs segregated based on following parameters that define the scope of the report, such as:
Natural Killer Cell Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Natural Killer Cell Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Natural Killer Cell Therapies drugs.
Natural Killer Cell Therapies Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Natural Killer Cell Therapies - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Natural Killer Cell Therapies: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cell abnormalities have been observed in several cancer patients, including decreased cytotoxicity, defective expression of activating receptors or intracellular signaling molecules, overexpression of inhibitory receptors, defective proliferation, and decreased numbers in peripheral blood and tumor infiltrate, and defective cytokine production. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. NK cell immunotherapy can be achieved in several ways
'Natural Killer Cell Therapies - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Natural Killer Cell Therapies pipeline landscape is provided which includes the disease overview and Natural Killer Cell Therapies treatment guidelines. The assessment part of the report embraces, in depth Natural Killer Cell Therapies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer Cell Therapies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer Cell Therapies R&D. The therapies under development are focused on novel approaches to treat/improve Natural Killer Cell Therapies.
This segment of the Natural Killer Cell Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Natural Killer Cell Therapies Emerging Drugs
- Monalizumab: Innate Pharma
- NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
- ALT 803: ImmunityBio
- ALECSAT: CytoVac
- PNK-007: Celularity
Further product details are provided in the report……..
Natural Killer Cell Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Natural Killer Cell Therapies drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Natural Killer Cell Therapies
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intracranial
- Intramuscular
- Intratumoral
- Intravenous
- Intravenous
- Parenteral
- Subcutaneous
- Molecule Type
- Small molecule
- Antibodies
- Beta Glucans
- CAR-NK cell therapy
- Cell Therapy
- Gene therapies
- Glycolipid
- NK Cell therapy
- NK T-Cell therapy
- Oligodeoxyribonucleotides
- Proteins
- RNA
- Stem cell therapies
- Vaccines
- Product Type
Natural Killer Cell Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Natural Killer Cell Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Natural Killer Cell Therapies drugs.
Natural Killer Cell Therapies Report Insights
- Natural Killer Cell Therapies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Natural Killer Cell Therapies drugs?
- How many Natural Killer Cell Therapies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Natural Killer Cell Therapies?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Natural Killer Cell Therapies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Natural Killer Cell Therapies and their status?
- What are the key designations that have been granted to the emerging drugs?
- ImmunityBio
- Five Prime Therapeutics
- Innate Pharma
- Nektar Therapeutics
- Cantargia
- CureTech
- Dynavax
- Cellid Company
- Kiadis Pharma
- Multimmune GmbH
- CytoVac
- XNK Therapeutics
- NantKwest
- Green Cross Corporation
- HiberCell
- Bristol-Myers Squibb
- Innate Pharma
- Affimed Therapeutics AG
- Wugen
- Abivax
- Glycostem Therapeutics (IPD Therapeutic)
- Synimmune
- GT Biopharma
- Bellicum Pharmaceuticals
- Asclepius Technology Company Group
- PersonGen BioTherapeutics (Suzhou)
- Chongqing Sidemu Biotechnology
- Artiva Biotherapeutics
- NKMax
- Acepodia
- Allife Medical Science and Technology
- Bright Path Biotherapeutics
- Kuur Therapeutics (Formerly Cell Medica)
- ALT 803
- Bemarituzumab
- Monalizumab
- NKTR-214 (Bempegaldesleukin)
- Nidanilimab
- Pidilizumab
- SD-101
- BVAC-C
- PD-L1.t-haNK
- K-NK002
- Enkastim
- ALECSAT
- CellProtect
- Nk-92
- haNk
- MG4101
- Imprime PGG
- Lirilumab
- IPH4102
- AFM-13
- WU-NK-101
- ABX196
- AFM24
- PNK-007
- Allogeneic Natural Killer Cell Therapy (oNKord)
- FLYSYN
- KNK-ID-101
- GTB-3550
- CAR-NK cells
- DF1001
- DF-6002
- NKG2D-ACE2 CAR-NK Cells
- AB-101
- SNK01
- NKTR-225
Introduction
Executive Summary
Natural Killer Cell Therapies: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Natural Killer Cell Therapies – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Monalizumab: Innate Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
ALECSAT: CytoVac
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
CYAD-02: Celyad Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CYT-501: Cytovia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Natural Killer Cell Therapies Key Companies
Natural Killer Cell Therapies Key Products
Natural Killer Cell Therapies- Unmet Needs
Natural Killer Cell Therapies- Market Drivers and Barriers
Natural Killer Cell Therapies- Future Perspectives and Conclusion
Natural Killer Cell Therapies Analyst Views
Natural Killer Cell Therapies Key Companies
Appendix
Executive Summary
Natural Killer Cell Therapies: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Natural Killer Cell Therapies – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Monalizumab: Innate Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
ALECSAT: CytoVac
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
CYAD-02: Celyad Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CYT-501: Cytovia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Natural Killer Cell Therapies Key Companies
Natural Killer Cell Therapies Key Products
Natural Killer Cell Therapies- Unmet Needs
Natural Killer Cell Therapies- Market Drivers and Barriers
Natural Killer Cell Therapies- Future Perspectives and Conclusion
Natural Killer Cell Therapies Analyst Views
Natural Killer Cell Therapies Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Natural Killer Cell Therapies
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Natural Killer Cell Therapies
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Natural Killer Cell Therapies
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Natural Killer Cell Therapies
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products